SERPINE1 and COVID-19: Also, a PAI-1 inhibitor (TM5614) has been investigated for treating patients with severe COVID-19 (Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19: Trial identifier NCT04634799, https://clinicaltrials.gov/ct2/show/NCT04634799?term=PAI-1$+$inhibitor&draw=2&rank=1).